Results 131 to 140 of about 5,135,152 (380)
A Common Gene Expression Signature Analysis Method for Multiple Types of Cancer [PDF]
2019 19th Industrial Conference on Data Mining, 2019 Mining gene expression profiles has proven valuable for identifying signatures serving as surrogates of cancer phenotypes. However, the similarities of such signatures across different cancer types have not been strong enough to conclude that they represent a universal biological mechanism shared among multiple cancer types.
arxiv
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Molecular Oncology, EarlyView.We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock +10 more
wiley +1 more source
Toward an integrated map of genetic interactions in cancer cells
Molecular Systems Biology, 2018 Cancer genomes often harbor hundreds of molecular aberrations. Such genetic variants can be drivers or passengers of tumorigenesis and create vulnerabilities for potential therapeutic exploitation.
Benedikt Rauscher +5 more
doaj +1 more source
Translational genomics in cancer research: converting profiles into personalized cancer medicine
Cancer Biology & Medicine, 2013 Cancer genomics is a rapidly growing discipline in which the genetic molecular basis of malignancy is studied at the scale of whole genomes. While the discipline has been successful with respect to identifying specific oncogenes and tumor suppressors ...
Lalit Patel +3 more
doaj +1 more source
Precision Therapeutic Biomarker Identification with Application to the Cancer Genome Project [PDF]
arXiv, 2017 Cancer cell lines have frequently been used to link drug sensitivity and resistance with genomic profiles. To capture genomic complexity in cancer, the Cancer Genome Project (CGP) (Garnett et al., 2012) screened 639 human tumor cell lines with 130 drugs ranging from known chemotherapeutic agents to experimental compounds. Questions of interest include:
arxiv
Annals of Applied Statistics, 2017 Recent advances in high-throughput biotechnologies have generated var-ious types of genetic, genomic, epigenetic, transcriptomic and proteomic data across different biological conditions.
Yuping Zhang, Z. Ouyang, Hongyu Zhao
semanticscholar +1 more source
Molecular Oncology, EarlyView.Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy +12 more
wiley +1 more source
F1000Research, 2015 Modern cancer genomics has emerged from the combination of the Human Genome Reference, massively parallel sequencing, and the comparison of tumor to normal DNA sequences, revealing novel insights into the cancer genome and its amazing diversity. Recent developments in applying our knowledge of cancer genomics have focused on the utility of these data ...
openaire +4 more sources
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Cancer, 2017 Classification of endometrial carcinomas (ECs) by morphologic features is irreproducible and imperfectly reflects tumor biology. The authors developed the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), a molecular classification ...
A. Talhouk +13 more
semanticscholar +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
Molecular Oncology, EarlyView.mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia +17 more
wiley +1 more source